An epidemiological investigation from Durham University reveals that the mental health benefits linked to classic psychedelics, such as psilocybin and LSD, vary significantly across human lifespans. Published in Scientific Reports, the study analyzed survey data from 1,088 adults aged 18 to 55 and older, evaluating lifetime psychedelic use alongside validated anxiety, depression, and well-being scales.
Researchers discovered that adults in their twenties and early thirties with a history of classic psychedelic use reported significantly lower levels of depression and anxiety compared to non-users. However, this mental health association diminished progressively with age and disappeared entirely in older cohorts, a divergence largely explained by the higher intensity of mystical-type experiences reported by younger individuals.
As psychedelic-assisted psychotherapy moves through advanced clinical trials for major depressive disorder, generalized anxiety, and treatment-resistant post-traumatic stress, neuroscientists are working to understand the demographic, psychological, and neurobiological parameters that dictate therapeutic efficacy.
While clinical trials focus on short-term symptom reduction under structured medical supervision, evaluating the long-term mental health footprints of naturalistic psychedelic use across diverse populations remains essential for establishing realistic clinical expectations.
Source: Neuroscience News — Read the full article on the original site ↗